Company / Financials
Niagen Bioscience, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$129.4M
FY2025 · +54.9% YoY
Net Income
$17.4M
FY2025 · +452.0% YoY
Profit Margin
13.4%
FY2025 · net income / revenue
ROE
22.7%
FY2025 · return on equity
Total Assets
$106.4M
FY2025
Total Debt
-
FY2025
Equity
$76.5M
FY2025
ROA
16.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$129.4M+54.9% YoYNet Income HistoryProfit after all expenses and taxes$17.4M+452.0% YoYGross Profit HistoryRevenue minus cost of goods sold$83.2M+63.8% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$46.2M+41.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes$16.3M+390.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$27.1M+8.3% YoYR&D Expense HistoryResearch and development spending$6.3M+27.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$3.0KIncome Tax HistoryTotal income tax expense$810.0KEPS (Basic) HistoryBasic earnings per share$0.11+257.1% YoY